Turkey Tail Mushroom

Trametes versicolor (Turkey Tail) extract, specifically PSK, for humans, the most commonly used dose of Trametes versicolor (Turkey Tail) extract, specifically PSK, in clinical studies and practice is 3 grams per day, often divided into multiple doses . This dosage has been used as an adjunct to conventional cancer treatment and is associated with improved survival outcomes . Doses up to 9 grams per day have been used in Japan. The provided results do not specify a standard dose for animals within a cancer protocol. While one of the user's initial notes mentions 100 mg/kg (divided 2–3 times daily), this specific dosage and its application are not confirmed. General toxicological assessments indicate that PSK and PSP have low toxicity in animals.

Artemisinin / Artesunate Pharmacy (sweet wormwood supplements) or compounded

Oral artemisinin 5–15 mg/kg/day. For humans, the only randomized, double-blind, placebo-controlled trial of artesunate in cancer used a dose of 200 mg of oral artesunate daily for 14 days . Other sources suggest that artemisinin-based drugs are being reviewed for their potential to improve cancer outcomes, but specific standard dosing regimens beyond this trial are not detailed. For animals, studies have used varying doses. In an animal model of stage II breast cancer, comparative studies were conducted on artemisinin, artesunate, and artemether, though exact dosages for this study are not specified. Another in vivo study used dosages ranging from 50 to 100 mg/kg/day of artemisinins, which showed little toxicity. In dogs with cancer, artesunate was administered at 950 mg divided into two daily doses (median effective dosage of 651 mg/m²) during days 1-85, later reduced to 800 mg per day. To minimize toxicities, a maximum dosage of 1200 mg/m² has been recommended in some canine studies. One rat study involved administering 3.5 mg/kg of artesunate once daily for four weeks.

Fenbendazole or Mebandazole (very similar chemical)

For humans, there is no established standard dose for fenbendazole or mebendazole in cancer treatment as their use is not FDA-approved for this purpose and clinical trial data is limited. However, based on anecdotal reports and repurposed protocols often discussed in integrative oncology circles, a common regimen cited involves mebendazole at 100–200 mg twice daily for three consecutive days per week (e.g., 3 days on, 4 days off), sometimes cycled over several weeks. One case report mentioned the use of fenbendazole at 1 g (1000 mg) taken orally once daily, combined with dietary changes and supplements, though this is not part of a standardized clinical protocol. For animals, fenbendazole is commonly used as an anthelmintic. A typical deworming dose in dogs and cats is 50 mg/kg orally once daily for three consecutive days. This "3 days on, 4 days off" schedule aligns with some repurposed cancer protocols observed in veterinary settings, particularly in canine cancer management, where it has been used off-label. For example, doses of fenbendazole ranging from 22.7 to 50 mg/kg/day for 3–5 days have been reported in dogs. Mebendazole has also been used in animals, though specific anti-cancer dosing in veterinary oncology is less well-documented.

Ivermectin

For humans, the antiparasitic dose of ivermectin is typically 150–200 µg/kg as a single oral dose. However, some preclinical studies suggest that higher doses may be required for anticancer effects, potentially exceeding standard antiparasitic dosing. A phase I clinical trial in cancer patients explored escalating doses of ivermectin from 30 to 90 mg weekly (equivalent to approximately 0.4–1.2 mg/kg for a 75 kg person), finding that doses up to 60 mg were well tolerated and achieved plasma concentrations associated with antitumor activity in vitro. This suggests that anticancer use may require prolonged low-dose administration or higher-than-standard parasitic doses, though such regimens remain investigational. For animals, ivermectin is widely used in veterinary medicine at species-specific doses. In dogs, the typical dose ranges from 6 to 12 µg/kg daily or every other day for parasite control (e.g., heartworm prevention), while much higher doses (up to 600 µg/kg) have been used in certain conditions like demodicosis under veterinary supervision. However, breeds with MDR1 gene mutations (e.g., Collies, Australian Shepherds) are highly sensitive to neurotoxicity at elevated doses. In rodent models, ivermectin has been administered at 0.2–0.4 mg/kg intraperitoneally or orally to evaluate antitumor effects. Despite promising in vitro data, there is limited published evidence on standardized anticancer dosing protocols in companion animals.

Cancer medications are by mutation which is determined by biopsy.

Each cancer type (and often subtype) is driven by different molecular abnormalities:

1. Lung cancer: EGFR, ALK, KRAS mutations
2. Leukemia: BCR-ABL fusion
3. Breast cancer: HER2 amplification, hormone receptors
4. Melanoma: BRAF V600E mutation

➡️ A drug like osimertinib shuts down mutant EGFR in lung cancer but does nothing in colon cancer if the same mutation isn't present or functional. Imatinib works brilliantly in CML (BCR-ABL+) but fails in most solid tumors without that target.

To choose any effective treatment, you need, Biopsy with histopathology – What kind of tumor? Molecular profiling – FISH, IHC, NGS panel. Without these, any drug choice is guesswork — and likely ineffective.

Chlorambucil (metronomic dosing)

1. Broad Activity + Low Guesswork + Clinical Evidence
2. Dose: 0.4–0.8 mg/kg daily
3. Mechanism: Alkylating agent; low-dose = anti-angiogenic + immunomodulatory
4. Evidence: Prospective canine studies in various cancers (lymphoma, solid tumors)
5. Breadth: Works across histologies (especially round-cell tumors), often combined with NSAIDs
6. No biomarkers needed
7. Toxicity: Very low (mild myelosuppression)
8. Widely used in veterinary oncology as a foundational metronomic chemo

Cyclophosphamide (metronomic)

1. Dose: 1–2.5 mg/kg daily (oral)
2. Mechanism: Similar to chlorambucil — anti-angiogenic at low doses
3. Evidence: Multiple supportive studies in dogs; synergistic with other TKIs
4. Used off-label in many carcinomas, sarcomas, lymphomas
5. Monitoring: Bladder health (rare hemorrhagic cystitis at metronomic dose)